BIOMARKER

• van Lier et al. J Intern Med, 2021;289(6):792-806
  “Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3”
• Blet et al. Crit Care, 2020;28;24(1):69
  “Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU”
• Lundberg et al. Crit Care, 2020;24(1):636
  “Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness”
• Kim et al. Ann Lab Med, 2019;39(5):454-463
  “Circulating biologically active adrenomedullin predicts organ dysfunction and mortality in sepsis”
• Lemasle et al. Crit Care, 2019; 48(1):49-55 
  ”Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill: Results from the French and European Outcome Registry in ICU”
• Caironi et al. Chest, 2017;152(2):312-320
  “Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis.”
• Marino et al. Crit Care, 2014;18(1):R34
  “Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis”

MODE OF ACTION

• Deniau et al. Expert Opin Investing Drugs, 2021;30(2):95-102
  “Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis”
• Geven et al. Shock, 2018;50(2):132-140
  “Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis”.
• Geven and Pickkers, Crit Care, 2018;22:159
  “The mechanism of action of the adrenomedullin-binding antibody adrecizumab”
• Geven et al. Front Immunol, 2018;9:292
  “Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis”

PRECLINICAL

• Thiele et al. Shock, 2020;54(6):810-818
  “Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model”
• Blet et al. Intensive Care Med Exp, 2019;7(1):25
  “Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats”
• Geven et al. Toxicol Appl Pharmacol, 2019;369:1-16 
  “Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates.”
• Gayat et al. Crit Care, 2018;22(1):8
  “Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study”
• Geven et al. Shock, 2018;50(6):648-54
  “Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis”
• Blet et al. Intensive Care Med Exp, 2015, 3(Suppl 1):A618
  “Hemodynamics effects of adrecizumab in sepsis rat”
• Zink et al. Shock, 2015;44(Suppl 2):15-16
  “SEP-7: Endothelial Barrier Injury is directly related to Kidney Dysfunction in resuscitated murine shock model”
• Struck et al. Intensive Care Med Exp, 2013;1:22 
  “Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model”
• Wagner et al. Intensive Care Med, 2013;1:21 
  “Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock”

CLINICAL

• Picckers et al. ISICEM 2024
  “Precision Medicine in Septic Shock with Enibarcimab – Biomarker Guided Definition of Target Population.“
• Van Lier et al. Frontiers in Med., (2022); 9:1058235
  “Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial“
• Laterre et al. Intensive Care Med, 2021;47(10):1284–1294
  “Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.”
• Karakas et al. Biomolecules, 2020;10:1171 
  “Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)”
• Geven et al. BMJ Open, 2019;9(2):e024475
  “A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)”
• Geven et al. Br J Clin Pharmacol, 2018;84(9):2129-2141 
  “Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects”
• Mebazza et al. Crit Care, 2018;22(1):354 
  “Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study”
• Mebazaa et al. J Intensive Care, 2016;4:24 
  “Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure”
• Sepsis bekämpfen – Leben retten